We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Rejects Avodart, Proscar for Prostate Cancer
FDA Panel Rejects Avodart, Proscar for Prostate Cancer
December 3, 2010
An FDA advisory committee has turned down GlaxoSmithKline (GSK) and Merck’s hopes of gaining approval for Avodart and Proscar as preventative treatments for prostate cancer.